Regular Article CLINICAL TRIALS AND OBSERVATIONS Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma
نویسندگان
چکیده
1Division of Hematology/Oncology and 2Helen Diller Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA; 3Genentech, South San Francisco, CA; 4Medical Oncology, Stanford University, Stanford, CA; 5Department of Neuro-oncology, Dana-Farber Cancer Center, Boston, MA; 6Department of Neuro-oncology, Massachusetts General Hospital, Boston, MA; 7Department of Neuro-oncology, Medical College of Wisconsin, Milwaukee, WI; and 8Biostatistics and Computational Biology Core, 9Department of Laboratory Medicine, and 10Department of Radiology, University of California, San Francisco, San Francisco, CA
منابع مشابه
CLINICAL TRIALS AND OBSERVATIONS Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo–purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group
Christian H. Geisler,1 Arne Kolstad,2 Anna Laurell,3 Niels S. Andersen,1 Lone B. Pedersen,1 Mats Jerkeman,4 Mikael Eriksson,4 Marie Nordström,5 Eva Kimby,5 Anne Marie Boesen,6 Outi Kuittinen,7 Grete F. Lauritzsen,2 Herman Nilsson-Ehle,8 Elisabeth Ralfkiær,1 Måns Åkerman,4 Mats Ehinger,4 Christer Sundström,3 Ruth Langholm,2 Jan Delabie,2 Marja-Liisa Karjalainen-Lindsberg,9 Peter Brown,1 and Erkk...
متن کاملCLINICAL TRIALS AND OBSERVATIONS CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)
One thousand two hundred twenty-two patients treated in the Rituximab with CHOP over age 60 years (RICOVER-60) trial were examined for central nervous system (CNS) disease developing during first-line therapy or after a complete or partial remission had been achieved. Patients received 6 or 8 courses of CHOP (cyclophosphamide, adriamycin, vincristine, prednisone) administered every 2 weeks (CHO...
متن کاملRegular Article CLINICAL TRIALS AND OBSERVATIONS Central nervous system relapse in peripheral T-cell lymphomas: a Swedish Lymphoma Registry study
• CNS involvement at relapse/ progression in PTCL occurred at a frequency similar to what is seen in aggressive B-cell lymphomas. • Outcome after relapse is generally very poor in patients with PTCL and is not significantly altered by presence of CNS involvement at relapse. Central nervous system (CNS) relapse in non-Hodgkin lymphoma (NHL) carries a very poor prognosis. Risk factors and outcome...
متن کاملCLINICAL TRIALS AND OBSERVATIONS A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30 hematologic malignancies
Phase 1 testing of SGN-30, a chimeric monoclonal antibody for the treatment of CD30 malignancies, was conducted in a multicenter study. To explore the safety profile and establish the maximum tolerated dose (MTD), 24 patients with refractory or relapsed Hodgkin lymphoma or CD30 nonHodgkin lymphoma received 6 weekly doses of intravenous SGN-30 at 4 dose levels (2, 4, 8, or 12 mg/kg). Serum conce...
متن کاملCLINICAL TRIALS AND OBSERVATIONS The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma
Given the significant activity and tolerability of bendamustine, rituximab, and bortezomib in patients with relapsed indolent and mantle cell non-Hodgkin lymphoma, and laboratory studies suggesting synergistic activity, we conducted a multicenter phase 2 study of the bendamustine/ bortezomib/rituximab combination. Patients with relapsed or refractory indolent and mantle cell lymphoma with adequ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2013